Tran Group - Haemostasis and Thrombosis

Research overview | Our people | Contact | Projects | Publications

Research overview

For patients with bleeding disorders, devise comprehensive diagnostic algorithms including genetic testing & undertake translational research to bring novel therapeutics to patients.

For patients with thrombotic disorders, better define the incidence, natural history and clinical outcome of venous thromboembolism, better define optimal management of VTE patients, & explore factors influencing clinical outcomes.

We are dedicated to advancing scientific knowledge through collaborative research and innovative projects. Our team brings together passionate researchers from diverse backgrounds, united by a commitment to excellence and discovery. We work closely in collaboration with the Haematology Clinical Research Unit (CRU, Alfred Hospital) and undertakes focused correlative studies with emphasis on biomarkers and patient outcomes

Our group specialises in multidisciplinary research, combining expertise in science, and clinical-focused outcomes. We strive to make a positive impact by addressing real-world challenges, gaps in clinical care to foster creativity, and nurture the next generation of Australian researchers.

Our people

Group Leader

Leave this here so that Accordion nested does not detect this CT as not existing.

Contact Us

For enquiries, collaborations, or more information about our research, please email info@researchgroup.com or visit us at our lab in Dublin.

We welcome visitors and partners keen to learn more about our work. Stay tuned for updates and upcoming events!

Current projects

PhD Candidates

  • Angela Huang - Defining outcomes and novel predictive biomarkers of anticoagulant related bleeding
  • Dr Elise Flynn - The Changing Treatment Landscape in Paediatric Haemophilia: Examining the Effects of Novel Therapies
  • Hadley Bortz - Systems to Improve Anticoagulation Management and Clinical Outcomes in High-Risk Hospitalised Patients
  • Dr Dani Robinson - Developing a novel multifunctional thrombolytic for the treatment of stroke

Selected publications since 2020

  1. Valente M, Leung S, Wu P, Oh D, Tran HAM, Choi P. Acute ischemic stroke and TIA whilst on anticoagulants - outcomes in the era of Direct Oral Anticoagulants. Int Med J 2020 50(1):110-113. ePub 17/01/2020.
  2. Campbell S, Mason J, Hunt S, Prasad R, Ambrose H, Tran HA. Acquired haemophilia and haemostatic control with recombinant porcine FVIII. Int Med Journal 2021 Feb;51(2):215-219. doi: 10.1111/imj.14773.
  3. Stevens HP, McFadyen J, Tran HA. Risk stratification of acute pulmonary embolism and determining the effect on chronic cardiopulmonary complications: The REACH Study. Thrombosis Haemostasis Open journal. 2020 4(1):E45-E50.
  4. Brennan Y, Parikh S, McRae S, Tran HA. The Australian experience with switching to extended half-life factor VIII and IX concentrates on behalf of the Australian Haemophilia Centres Directors’ Organisation.  Haemophilia. 2020 May;26(3):529-535.
  5. Lim MS, Nandurkar D, Jong I, Cummins A, Tran HA, Chunilal S. Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism. J Thromb Thrombolysis. 2020 Feb;49(2):220-227.
  6. Stevens H, Peter K, Tran HA, McFadyen J. Predicting the risk of venous thromboembolism. J Clin Med 2020 May 22;9(5):1582. doi: 10.3390/jcm9051582.
  7. Oldenburg J, Tran HA, Peyvandi F, Nunez R, Trask P, Chebon S, Mahlangu J, Lehle M, Jimenez-Yuste V, von Mackensen S. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—a non-interventional study. Haemophilia. 2021 27(3):398-407. doi: 10.1111/hae.14270.
  8. Bui T, Bortz H, Corella C, Tran HA, Cheng A, Dooley M. AAA Stewardship: managing high-risk medications with dedicated Antimicrobial, Anticoagulation and Analgesic Stewardship programs. Journal of Pharmacy Practice and Research. Jul 16 2021, https://doi.org/10.1002/jppr.1716
  9. Yuen A, Tran HA, Chunilal SD. Upper Extremity Deep Vein Thrombosis: Current Knowledge and Future Directions. Recent Advances in Thrombosis and Hemostasis. https://doi.org/10.1055/s-0041-1725116. Epub 10/05/2021
  10. Hocking J, Chunilal SD, Chen V, Brighton T, Nguyen J, Tan, J, Ting SB, Tran HA. The first known ChAdOx1 nCoV-19 Vaccine-induced thrombotic cytopenia in Australia. Med J Aust 2021 Jul;215(1):19-20.e1. doi: 10.5694/mja2.51135. Epub 2021 Jun 11.
  11. Chen V, Curnow JL, Tran HA Choi PY. Australian New Zealand approach to diagnosis and management of vaccine induced immune thrombosis and thrombocytopenia. Med J Aust. 2021 Sep 20;215(6):245-249
  12. McFadyen J, Sharma P, Moon M, Noonan J, Goodall E, Tran HA, Peter K. Activation of circulating platelets in vaccine-induced thrombotic thrombocytopenia (VITT) and its reversal by intravenous immunoglobulin. In press Br J Haem July 25 2021. 2022 196(1):234-37
  13. Choi PY, Hsu D, Tran HA, Tan CW, Enjeti A, Chen VMY, Chong BH, Curnow J, Pepperell D, Bird R. Immune thrombocytopenia following vaccination during the COVID-19 pandemic. Haematologica 2022;107(5):1193-6.
  14. Merriman E, Chunilal S, Brighton T, Crowther H, Slocombe A, Tran HA. Two Weeks of Low Molecular Weight Heparin for Isolated Symptomatic Distal Vein Thrombosis (TWISTER study). Thrombosis Research. 207 (2021) 33–39 DOI:https://doi.org/10.1016/j.thromres.2021.09.004
  15. Yuen A, Zhao J, Tran HA, Chunilal SD. Development of a risk score to predict peripherally inserted central catheter thrombosis in active cancer". Int Med J. http://doi.org/10.1111/imj.15557
  16. S Gordon, H Clothier, H Morgan, J Buttery, L Phuong, P Monagle, S Chunilal, E Wood, HA Tran, J Szer, N Crawford. Immune thrombocytopenia following immunisation with Vaxzevria (AstraZeneca) vaccine, Victoria, Australia. Vaccine. 2021;39(48):7052-57
  17. Greinacher A, Langer F, Makris M, Pai M, Pavord S, Tran HA, Warkentin TE. Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources. J Thromb Haemost 2021. https://onlinelibrary.wiley.com/doi/10.1111/jth.15572
  18. Greinacher A, Langer F, Makris M, Pai M, Pavord S, Tran HA, Warkentin TE."Vaccine-induced immune thrombotic thrombocytopenia (VITT) - update on diagnosis and management considering different resources: Response to Comment from Yamada et al.,"
  19. Stevens H, Caanovas R, Peter K, Tran HA, McFadyen J. Inherited Thrombophilias are Associated With an Increased Risk of COVID-19 Associated Venous Thromboembolism: A Prospective Population-Based Cohort Study. Circulation In Press. CIRCULATIONAHA/2021/057394D.
  20. Dix C, Tee A, McFadyen J, Tran HA. Acquired Haemophilia A: Insight into treatment and outcomes from an Australian tertiary referral centre. Haemophilia. Haemophilia. 2022 Mar;28(2):e49-e52. doi: 10.1111/hae.14481
  21. Kenet G, Chen YC, Lowe G, Percy C, Tran HA, von Drygalski A, Trossaert M, Reding M, Oldenburg J, Mingot-Castellano ME, Park YS, Peyvandi F, Ozelo MC, Mahlangu J, Quinn J, Huang M, Reddy D, Kim K. Real-world rates of bleeding, factor VIII use, and quality of life in individuals with severe haemophilia A receiving prophylaxis in a prospective, noninterventional study. J Clin Med. 2021 Dec 18;10(24):5959. doi: 10.3390/jcm10245959
  22. Day D, Bortz H, Chunilal SD, Tran HA. Management of Isolated distal vein thrombosis in trauma patients – A single centre retrospective review. Injury 2022;53(7):2562-6.
  23. Dix, C, McFadyen, J, Huang, A, Chunilal, S.D, Chen, V.M, Tran, HA. Understanding vaccine-induced thrombotic thrombocytopenia (VITT). Int Med J 2022;52: 5, p. 717-723
  24. C Lee, H Liang, D Connor, A Dey, I Tohidi-Esfahani, H Campbell, S Whittaker, D Capraro, E J Favaloro, D Donikian, M Kondo, S M Hicks,P Y-I Choi, E E Gardiner, L Clarke, HA Tran, F H Passam, T Brighton, V M Chen. A novel flow cytometry procoagulant assay for diagnosis of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). Blood Advances (2022) 6 (11): 3494–3506 .https://doi.org/10.1182/bloodadvances.2021006698.
  25. L Brichko, L Van Breugel, A Underhill, HA Tran, B Mitra, P Cameron, D Smit, ML Giles, D McCreary, A Paton, G O’Reilly. Vacc-in-ED: The impact of COVID-19 vaccinations on Emergency Department presentations. Emergency Medicine Australasia.2022 April 27.
  26. Petkovic MJ, Tran HA, Ebeling PR, Zengin A. Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines. Haemophilia 15 Mar 2022. https://doi.org/10.1111/hae.14540.
  27. Clements W, Ban J, Joseph T, Marshal E, Lukies M, Koukounaras J. Tran HA, A retrospective study assessing the incidence of inferior vena cava (IVC) occlusion following prophylactic IVC filter insertion: is anticoagulation necessary during filter dwell? Injury. 2022;53(8):2763-7
  28. Hiu Lam Agnes Yuen, Ee Tan, Huyen Tran and Sanjeev Chunilal. Idiopathic upper extremity deep vein thrombosis: A systematic review. European Journal of Haematology. 2022;109(5):542-558
  29. Favaloro E; Clifford J; Leitinger E; Parker M, Sung P; Chunilal S; Tran H; Kershaw G; Fu S; Passam F; Ahuja M; Shadood N; Ho SJ; Duncan E; Yacoub O; Tan CW; Kaminskis L; Modica N; Pepperell D; Beggs J; Ballard L; Clarke L; Lee C; Gardiner E; Choi P; Tohidi-Esfahani I; Brighton T; Chen V. Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicentre study comprising 1284 patients . J Thromb Haemost 2022;20(12):2896-2908
  30. Yuen A, Tran HA, Chunilal SD. Upper extremity superficial vein thrombophlebitis – are we overtreating. Int Med J. 2022;52(11):1995-7. Article DOI: 10.1111/imj.15951
  31. Choi P, Tran HA, Hsu D, Immune thrombocytopenia and COVID-19 vaccination: outcomes and comparisons to pre-pandemic patients. RPTH 2023;7(1):100009
  32. Windyga J, Apte S, Frei-Jones M, Fujii T, Lyu CJ, Martinez L, Sathaa J, Stasyshyn S, Tran HA, Zozylya N, Frandsen R, Skov Neergaard J, Thaung Zaw J, Mahlangu. Unmet needs of patients with haemophilia A/B with or without inhibitors: Historical and baseline characteristics from patients entering a non-interventional study.
  33. A. Buoninfante, A. Andeweg, A. Baker, M. Borad, N. Crawford , JM Dogné, D. Garcia Azorin, A. Greinacher, R. Helfand, A. Peter Hviid , S. Kochanek, M. López-Fauqued, I. Nazy, A. Padmanabhan , S. Pavord, D. Prieto-Alhambra, HA Tran, U. Wandel Liminga  , M. Cavaleri. Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: a meeting report of the European Medicines Agency workshop. NPJVACCINES. 2022;7(1):141
  34. Bortz H, Shi I, Chee A, Tran HA. High rate of false-positive postoperative venous thromboembolism identified using hospital ICD-10 coding. Internal Medicine Journal 2023;53(1):126-30.
  35. Stevens HP,Bortz H, Chao S,…Tran HA. Improving the rate of inferior vena cava filter retrieval through multidisciplinary engagement. RPTH 2023;7(1):100040
  36. Dix C, Kerr M, McFadyen JD, Tran HA. Treatment of haematuria with factor concentrate in people with haemophilia is associated with low rates of complications. Haemophilia 2023 29(1):401-3. DOI: 10.1111/hae.14726
  37. FJ. Ryan, TS. Norton, CMcCafferty, SJ. Blake, NE. Stevens, JJames, GL. Eden, YC. Tee, SC. Benson,  MG. Masavuli, AEL Yeow, AAbayasingam, D.Agapiou, HP Stevens, J Zecha, NL. Messina, N Curtis, V Ignjatovic, P Monagle, HA Tran, JD. McFadyen, RA. Bull, B Grubor-Bauk, MA. Lynn, R Botten, SE. Barry, DJ. Lynn. A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA (BNT162b2/mRNA-1273) and adenovirus vectored vaccines (ChAdOx1-S) after the first, second and third doses. Cell Reports Medicine 2023 4, 100971.
  38. G. Young, A. Srivastava, K. Kavakli, L. Wong, C. Ross; J Sathar, C You; HA Tran, R Wu, S Poloskey, Z Qui, S Kichou, S Andersson, B Mei, S Rangarajan. Efficacy And Safety of Fitusiran Prophylaxis, An siRNA Therapeutic in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHwI). The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00284-2/fulltext
  39. Dix C, Tran HA, Venous anomalies and thromboembolism. Thrombosis Journal (2023) 21:45 https://doi.org/10.1186/s12959-023-00484-5
  40. T. Matsushita, A. Shapiro MD, A. Abraham, P. Angchaisuksiri,G. Castaman, K. Cepo, R. d’Oiron , M. Frei-Jones, A. Goh, J. Haaning, S. Hald Jacobsen MSc, 6 Johnny Mahlangu MBBCh, 10 Mary Mathias, K. Nogami, J. Skovgaard Rasmussen, O. Stasyshyn, H.A Tran , K. Vilchevska, L Villarreal Martinez, J. Windyga, C. Woo You, N. Zozulya, B. Zulfikar, V. Jiménez-Yuste. The phase 3 study of concizumab in hemophilia with inhibitors. New Eng J Med. In Press.
  41. L. Clarke, T. Brighton, S. Chunilal, F. Passam, J. Curnow, D. Hsu, V. Chen, H.A Tran. Vaccine-induced Immune Thrombotic Thrombocytopenia Post Dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem. Vaccine. 2023 Apr 19;S0264-410X(23)00379-1. doi:10.1016/
  42. Carly George, Sumit Parikh, Simon McRae, Tina Carter, Alison Morris, Cameron Cramey, Kymberley McElroy, Huyen A Tran. Haemophilia Joint Health Score (HJHS) usage, patterns and outcome data in patients with haemophilia A and haemophilia B in Australia: a descriptive study using the Australian Bleeding Disorders Registry (ABDR). Haemophilia. Haemophilia. 2023;29:1135–1141 https://doi.org/10.1111/hae.14812
  43. Baker R, Gilmore G, Tran HA, Brighton T, Curnow J, Joseph J. Emergency management of patients on direct oral anticoagulants or Vitamin K antagonists – a real-world comparison. RPTH 2023.
  44. C Lee, L Clarke, GKershaw, TBrighton, S Chunilal, E Favaloro, H Tran, and V Chen.  Platelet-activating functional assay resolution in VITT: differential alignment to PF4 ELISA. RPTH 2023 Mar 25;7(3):100128.
  45. Dix C, Day T, Bortz H, da Gama M, Treolar M, Tran HA. Adherence and persistence to Direct Oral Anticoagulants (DOACs) in the community following newly diagnosed Venous Thromboembolism (VTE) – a pharmacy-linkage study. Journal of Pharmacy Practice. In Press
  46. Tran H.A, Deng L, Wood N, Choi P, Singleton S, Clarke L, Khanlari S, Maitland-Scott I, Bird R, Brown S, Manoharan B, Tan CW, Flood L, Gold M, Hissaria P, Melody S,Chunilal S, Buttery J, Clothier H, Crawford NW, Phuong L, Pepperell D, Effler P, Parker C, Carter N, Macartney K, McStea M, Miller T, Nissen M, Larter C, Kay E, ChenV.M. The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia. Lancet Regional Health - Western Pacific The Lancet Regional Health -Western Pacific 2023;40: 100894
  47. George C, Carter T, McCosker J, Carlino S, Tran HA. Evaluation of treatment and outcome for patients with haemophilia A and haemophilia B on extended half-life (EHL) factor products: a 12-month data analysis. Haemophilia. 2023 29(5):1283-90
  48. Ramanan R, McFadyen J, Perkins A, Tran HA. Congenital Fibrinogen Disorders – Strengthening Genotype-Phenotype Correlations through Novel Genetic Diagnostic Tools. British Br J Haematol. 2023 Nov;203(3):355-368. Article DOI: 10.1111/bjh.19039
  49. Keragala C, McFadyen J,  Monagle P, Chunilal S, Stevens H, McCutcheon F, HO H, Liu Z, Medcalf R, Tran HA. Plasma from patients with Vaccine-induced immune thrombotic thrombocytopenia displays increased fibrinolytic potential and enhances tPA but not uPA-mediated plasminogen activation. J Thromb Haemost 2024 Mar;22(3):785-793. doi: 10.1016/j.jtha.2023.10.027.
  50. Tran H, Yang R, Fischer K, Makris M, Konkle B. The importance and evolution of bleeding disorder registries. Haemophilia. 2024;30(Suppl. 3):21–28. DOI: 10.1111/hae.14993
  51. Ramanan R, Evans N, Kaplan Z, McFadyen J, Tran HA. Mutational landscape, inhibitor development, and health-care burden in non-severe haemophilia A: A single-centre Australian experience. Haemophilia. 2024; 30:638–647. DOI: 10.1111/hae.15007
  52. Ramanan. R, Parikh S, Aung L.L, McFadyen J, Tran H.A. Intraindividual bleeding outcomes in patients with hemophilia A on emicizumab prophylaxis in Australia. Blood Vessels, Thrombosis & Hemostasis (2024) 1 (1): 100005. https://doi.org/10.1016/j.bvth.2024.100005
  53. So J, Dix C, Clements W, Gibbs H, Tran HA, McFadyen J. Venous anomalies - an under-recognized but important cause of venous thromboembolism. Blood Vessels, Thrombosis & Hemostasis. 2024. https://doi.org/10.1016/j.bvth.2024.100013
  54. Ramanan R, McFadyen J, Perkins A, Tran HA. Variants leading to dysfibrinogenemia in the fibrinogen a-chain at residue Arg19 are not solely associated with bleeding, but also with thrombotic events – RESPONSE. Br J Haematology. 2024. DOI: 10.1111/bjh.194
  55. H.A Tran, S. von Mackensen, A. Abraham, G. Castaman, K. Hampton, P. Knoebl, S. Linari, J. Odgaard-Jensen, J. S. Neergaard, O. Stasyshyn, J.J Thaung Zaw, B. Zulfikar, A. Shapiro. Concizumab prophylaxis for treatment of patients with haemophilia A or B with inhibitors: Patient-reported outcome results from the phase 3 explorer7 study. In Press. RPTH Jan 2024
  56. Windyga, J; Apte, S; Frei-Jones, M; Fujii, T; Lyu, C J; Villarreal-Martinez, L; Sathar, J; Stasyshyn, O; Tran, HA; Zozulya, N; Frandsen, R Neergaard, J S; Zaw, J J T; Mahlangu, J. Disease and treatment burden of patients with haemophilia entering the explorer6 non-interventional study. Submitted. European J of Haematology. In press DOI: 10.1111/ejh.14277.
  57. Schönborn L, Pavord S, Chen VMY, Pai M, Gwarzo DH, Buttery J, Munoz FM, Tran H, Greinacher A, Law B. Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine. 2024 Mar 7;42(7):1799-1811. doi: 10.1016/j.vaccine.2024.01.045. Epub 2024 Feb 1.PMID: 38302339
  58. Huang WT, Law B, Tran H, Schönborn L, Huang WI, Buttery J, Chen VMY, Greinacher A, Pavord S. Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis. Vaccine. 2024 Jul 12:S0264-410X(24)00794-1. doi: 10.1016/j.vaccine.2024.07.032.
  59. Bortz. H, Chee A, Tran. HA. Attention to the risk of venous thromboembolism in mechanically restrained hospitalised patients. Internal Medicine Journal. 2024.
  60. P. Chowdary, P. Angchaisuksiri, S. Apte, J. Astermark, G. Benson, A. Chan, V. Jiménez Yuste, T. Matsushita, A. Rhode Høgh Nielsen, J. Sathar, C, Sutton, S. Šaulytė Trakymienė, H. Tran, L. Villarreal Martinez, A.P. Wheeler, J. Windyga, G. Young, J.J Thaung Zaw, H. Eichler. Phase 3 Trial of Concizumab in Hemophilia without Inhibitors. 2025 In press. Lancet Haematology. https://doi.org/10.1016/S2352-3026(24)00307-7.
  61. Hannah Stevens, James D. McFadyen, Natalie A. Mellett, David J. Lynn, Thy Duong, Corey Giles, Jane James, Rochelle Botten, Georgina Eden, Miriam Lynn, Paul Monagle, Peter J. Meikle, Sanjeev Chunilal, Karlheinz Peter, Huyen Tran. Beyond Platelet Activation: Dysregulated Lipid Metabolism in Defining Risk and Pathophysiology of VITT. RPTH. https://doi.org/10.1016/j.rpth.2025.102677
  62. A. Dupuy, X. Liu, Y. Kong, M. Qi, J. Perdomo, J. Tieng, B. Johnston, Q. S Shi, M. Larance, Y. Zhang, L. A Ju, P. Coleman, J. Gamble, E. Gardiner, M. Poncz, H. A Tran, V. Chen, F. H Passam. Endothelial cell activation enhances thrombo-inflammation in vaccine-induced immune thrombotic thrombocytopenia. Blood Adv. In Press 2025
  63. Y.Chen, N. Louis, A. Huang, A. Sun, A. Dupuy , T. Pelaia, J. Ren, T. Cohen, S. Gilbert, H. Tran, K. Peter, J. McFadyen, L. Ju. Force-sensitive integrin αIIbβ3 activation mediates ChAdOx1 nCoV-19 vaccine– platelet interactions under shear conditions. Blood. In Press 2025.
  64. R. Ramanan, Christine Van Laer, S. Baert, C. Kint, C.Van Geet, Q Van Thillo, P. Verhamme1, T. Vanassche, J.D. McFadyen, A.C. Perkins, H.A. Tran2,3 | V. Labarque, K. Freson. Clinical utility of panel-based genetic sequencing for von Willebrand disease. Res Pract Thromb Haemost. https://doi.org/10.1016/j.rpth.2025.102730
  65. C.B. Russell, C. Vettermann, S. Agarwal, E. Witt, W. Clark, J. Arens, R. Fronza, K. Obrochta, T. Seitel, T.M. Robinson, H.A Tran, G. Kenet, P. Raheja, W. Lester, K. Eggan, S. Zoog. Recombinant AAV integration profiles in non-human primates and gene therapy participants after treatment with valoctocogene roxaparvovec. Human Gene Therapy. ePUB June 2025.  https://doi.org/10.1089/hum.2024.236
  66. K. Kavakli, A. Cuker, L. Frenzel, J.D Wang, CN. Bagot, A. Lienhart, F. Sahin, HA. Tran, H. Alzahrani, D. Matino, J. Rupon, J. Fuiman, J. McKay, M. de los Angeles Resa, LJ Wilcox, F. Biondo, D. Agathon, S. Thakkar, P. Sun, F. Plonski, S. von Mackensen. Health-related Quality of Life in Adults With Hemophilia B After Gene Therapy With Fidanacogene Elaparvovec: Results from the BENEGENE-2 trial. J Thromb Haemostasis. In Press